By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Fibric acid derivatives > Gemfibrozil > Gemfibrozil Dosage
Fibric acid derivatives
https://themeditary.com/dosage-information/gemfibrozil-dosage-503.html

Gemfibrozil Dosage

Drug Detail:Gemfibrozil (Gemfibrozil [ jem-fye-broe-zil ])

Drug Class: Fibric acid derivatives

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Hyperlipidemia

600 mg orally twice a day, 30 minutes before the morning and evening meals

Uses: As an adjunct to diet in the following situations: to treat hypertriglyceridemia in Types IV and V hyperlipidemia in patients who present at risk for pancreatitis and who do not respond adequately to diet; to reduce the risk for coronary heart disease (CHD) only in Type IIb patients without a history of or symptoms of existing CHD who have not responded adequately to other pharmacologic agents and nonpharmacologic interventions and who have low high density lipoprotein (HDL), elevated low density lipoprotein (LDL), and elevated triglycerides

Usual Adult Dose for Hyperlipoproteinemia Type IIb (Elevated LDL + VLDL)

600 mg orally twice a day, 30 minutes before the morning and evening meals

Uses: As an adjunct to diet in the following situations: to treat hypertriglyceridemia in Types IV and V hyperlipidemia in patients who present at risk for pancreatitis and who do not respond adequately to diet; to reduce the risk for coronary heart disease (CHD) only in Type IIb patients without a history of or symptoms of existing CHD who have not responded adequately to other pharmacologic agents and nonpharmacologic interventions and who have low high density lipoprotein (HDL), elevated low density lipoprotein (LDL), and elevated triglycerides

Usual Adult Dose for Hyperlipoproteinemia Type IV (Elevated VLDL)

600 mg orally twice a day, 30 minutes before the morning and evening meals

Uses: As an adjunct to diet in the following situations: to treat hypertriglyceridemia in Types IV and V hyperlipidemia in patients who present at risk for pancreatitis and who do not respond adequately to diet; to reduce the risk for coronary heart disease (CHD) only in Type IIb patients without a history of or symptoms of existing CHD who have not responded adequately to other pharmacologic agents and nonpharmacologic interventions and who have low high density lipoprotein (HDL), elevated low density lipoprotein (LDL), and elevated triglycerides

Usual Adult Dose for Hyperlipoproteinemia Type V (Elevated Chylomicrons + VLDL)

600 mg orally twice a day, 30 minutes before the morning and evening meals

Uses: As an adjunct to diet in the following situations: to treat hypertriglyceridemia in Types IV and V hyperlipidemia in patients who present at risk for pancreatitis and who do not respond adequately to diet; to reduce the risk for coronary heart disease (CHD) only in Type IIb patients without a history of or symptoms of existing CHD who have not responded adequately to other pharmacologic agents and nonpharmacologic interventions and who have low high density lipoprotein (HDL), elevated low density lipoprotein (LDL), and elevated triglycerides

Usual Adult Dose for Hypertriglyceridemia

600 mg orally twice a day, 30 minutes before the morning and evening meals

Uses: As an adjunct to diet in the following situations: to treat hypertriglyceridemia in Types IV and V hyperlipidemia in patients who present at risk for pancreatitis and who do not respond adequately to diet; to reduce the risk for coronary heart disease (CHD) only in Type IIb patients without a history of or symptoms of existing CHD who have not responded adequately to other pharmacologic agents and nonpharmacologic interventions and who have low high density lipoprotein (HDL), elevated low density lipoprotein (LDL), and elevated triglycerides

Usual Adult Dose for Prevention of Cardiovascular Disease

600 mg orally twice a day, 30 minutes before the morning and evening meals

Uses: As an adjunct to diet in the following situations: to treat hypertriglyceridemia in Types IV and V hyperlipidemia in patients who present at risk for pancreatitis and who do not respond adequately to diet; to reduce the risk for coronary heart disease (CHD) only in Type IIb patients without a history of or symptoms of existing CHD who have not responded adequately to other pharmacologic agents and nonpharmacologic interventions and who have low high density lipoprotein (HDL), elevated low density lipoprotein (LDL), and elevated triglycerides

Renal Dose Adjustments

Severe renal dysfunction: Contraindicated

Liver Dose Adjustments

Hepatic dysfunction (including primary biliary cirrhosis): Contraindicated

Precautions

CONTRAINDICATIONS:

  • Hypersensitivity to the active component or any product ingredients
  • Preexisting gallbladder disease
  • Hepatic dysfunction (including primary biliary cirrhosis)
  • Severe renal dysfunction
  • Concomitant use with simvastatin, replaglinide, dasabuvir, or selexipag

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Take orally twice a day, 30 minutes before the morning and evening meals
  • Administer 2 hours or more apart from bile acid-binding resins

Storage requirements:
  • Store at controlled room temperature; protect from light and humidity

General:
  • Prior to initiating treatment, every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities.
  • Treatment is not indicated for patients with Type I hyperlipoproteinemia who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL), nor is it indicated in patients with low HDL as their only lipid abnormality.
  • Due to the potential for toxicity, this drug is not indicated for treatment in patients with Type IIa elevations of LDL when this is the only abnormality.

Monitoring:
  • Hepatic: Periodically measure liver function tests.
  • Hematologic: Measure blood counts periodically during first 12 months of therapy.
  • Metabolic: Periodically measure serum lipid levels; treatment should be withdrawn if lipid response is inadequate after 3 months of therapy.

Patient advice:
  • Advise patients to report muscle pain, weakness, or tenderness, immediately.
  • Patients should talk to their health care provider if they are pregnant, planning to become pregnant, or breastfeeding.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by